CALC CBO Eric Roberts added 3,508 shares at $2.79

Aug 25

CALC #CALC — CalciMedica Inc | Healthcare |Biotechnology | USA |NASD | August 25, 2025.

Insider Purchase and Company Overview

Recent insider activity at CalciMedica Inc. (NASDAQ: CALC), a clinical-stage biotechnology company focused on developing novel therapies for acute and chronic inflammatory diseases, indicates growing executive confidence.

On August 21, 2025, Eric W. Roberts, the Chief Business Officer, purchased 3,508 shares at an average price of $2.79 per share, for a total value of $9,797. This transaction, disclosed via SEC Form 4 on August 25, 2025, at 09:30 AM EDT, increased his total holdings to 60,907 shares. This buy is part of a broader pattern of insider accumulation, as CalciMedica's Chief Medical Officer, Sudarshan Hebbar, also acquired shares in mid-August 2025 (9,563 shares on August 19 at ~$2.82 and 4,392 shares on August 15 at ~$2.79), signaling potential optimism amid the stock's recent volatility.

• stocktitan.net/sec-filings/CALC/form-4-calci-medica-inc-insider-trading-activity-01969e55b9c1.html
• investing.com/news/insider-trading-news/hebbar-calcimedica-cmo-buys-16k-in-calc-stock-93CH-4198177

The company reported Q2 2025 earnings on August 12, 2025, with a net loss of $6.0 million ($0.40 per share), in line with analyst estimates, and a cash position of $18.0 million as of June 30, 2025—sufficient to fund operations into mid-2026.

Key catalysts include ongoing Phase 2 trials (e.g., KOURAGE for acute kidney injury, with data expected in 2025), which could drive upside if positive.

• ir.calcimedica.com/news-releases/news-release-details/calcimedica-reports-second-quarter-2025-financial-results-and
• prnewswire.com/news-releases/calcimedica-reports-second-quarter-2025-financial-results-and-provides-clinical--corporate-updates-302526849.html
• stocktitan.net/news/CALC/calci-medica-reports-second-quarter-2025-financial-results-and-olp7rrfog9j7.html

Analysis Based on Insider Data

The cluster of insider buys in August 2025, including Roberts' purchase at $2.79, aligns with the chart's bottoming signals and post-earnings stability. Insiders often buy during perceived undervaluation, especially in biotech where clinical data can catalyze rapid moves.

With cash runway to mid-2026 and upcoming trial readouts, this activity implies executives see asymmetric upside potential, potentially discounting positive Phase 2 results. The buys occurred near support levels, reinforcing the $2.50-$2.80 zone as a accumulation area.

Charts:

• (1D)

• (1D)

• (3D)


SEC From 4:
sec.gov/Archives/edgar/data/1534133/000141588925022850/xslF345X05/form4-08252025_090801.xml

Forecast:

Replicating Roberts' buy at ~$2.79, the setup offers moderate-to-high reward potential in a biotech rebound play, assuming positive catalysts materialize. Based on the insider confidence, technical bottoming, and upcoming data, I project a 40-80% upside potential over 3-6 months if the reversal holds.

Entry Price: $2.79 (current/insider level).

Recommended Exit Targets:

— Conservative Target 1: $3.50 (25% profit, +$0.71/share) – Near-term resistance; exit on first signs of weakness or post-trial news.
— Moderate Target 2: $4.00 (43% profit, +$1.21/share)
— Aggressive Target 3: $5.00 (79% profit, +$2.21/share) – full exit if RSI hits overbought (>70) or on positive trial data release.

Overall Potential: 40-80% growth.

This forecast is speculative and not financial advice; always conduct due diligence.

Sep 10

Trade active

CALC #StockMarket #Investing — CalciMedica Inc | Healthcare |Biotechnology | USA |NASD | September 10, 2025.




News That Likely Drove CALC (CalciMedica) Stock Growth from August 25 to September 10, 2025

➖ August 28–29, 2025: Additional Insider Purchases by Chief Business Officer Eric W. Roberts
Eric W. Roberts continued insider buying, snapping up 9,200 shares at $2.86 and 800 shares at $2.74, signaling strong confidence in the company’s outlook.

➖ September 2, 2025: Announcement of Participation in H.C. Wainwright 27th Annual Global Investment Conference CEO Rachel Leheny, Ph.D., is set to present on September 8, 2025, at 3:30 p.m. ET, discussing CRAC channel inhibition therapies for inflammatory diseases, boosting the company’s visibility among investors.

Upcoming Expected News and Events

➖ September 8, 2025: CEO Presentation at H.C. Wainwright 27th Annual Global Investment Conference
Rachel Leheny, Ph.D., will provide an overview of Auxora™ clinical programs, with a webcast available on the company’s website.

➖ Mid-2025: End-of-Phase 2 Meeting with FDA for Auxora in Acute Pancreatitis (AP)
A meeting is planned to discuss the design of a pivotal Phase 3 trial; constructive discussions with the FDA are already underway.

➖ End of 2025: Alignment on Pivotal Phase 3 Trial Design for Auxora in AP with SIRS
FDA alignment is expected for launching the Phase 3 program, contingent on additional funding. This would mark the first pivotal trial in the U.S. for AP therapy.

➖ November 2025: Q3 2025 Financial Results Report
Set for release on November 6, 2025, with updates expected on cash position ($18M as of Q2, sufficient through mid-2026) and trial progress.

Early 2026: Topline Data from Phase 2 KOURAGE Trial for Auxora in AKI with Respiratory Failure
Results from enrolling 150 patients are anticipated, with prior post-hoc analysis showing a 62.7% reduction in mortality.

My View:
Hit the first Take Profit target at $3.50 (+25.45%).

Remaining targets:

Take Profit 2: $4.00
Take Profit 3: $5.00